SCHEMBL1913664

SCHEMBL1913664

O=P(Cl)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.64
KMT2A Q03164 3/20 0.64
HPGD P15428 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.46
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
CA1 P00915 1/20 0.41
LMNA P02545 4/20 0.41
NPSR1 Q6W5P4 3/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.41
CYP2A6 P11509 1/20 0.40
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9549528 0.87 MEN1 (0.55) MEN1KMT2AHPGDSMN1; SMN2CYP1A2
SCHEMBL561706 0.85 MEN1 (0.64) MEN1KMT2AHPGDSMN1; SMN2CYP1A2
SCHEMBL1059937 0.82 MEN1 (0.67) MEN1KMT2AHPGDSMN1; SMN2CYP1A2
SCHEMBL20795780 0.82 MEN1 (0.50) MEN1KMT2AHPGDSMN1; SMN2CYP1A2
SCHEMBL24082140 0.81 MEN1 (0.59) MEN1KMT2AHPGDSMN1; SMN2CYP1A2
SCHEMBL10622033 0.81 MEN1 (0.59) MEN1KMT2AHPGDSMN1; SMN2CYP1A2
SCHEMBL11507769 0.78 MEN1 (0.61) MEN1KMT2AHPGDSMN1; SMN2CYP1A2
SCHEMBL11839604 0.78 LMNA (0.44) MEN1KMT2ACA2CA9CA1
SCHEMBL9621857 0.78 CA1 (0.52) HPGDCA2CA9CA1LMNA
SCHEMBL1059938 0.78 MEN1 (0.61) MEN1KMT2AHPGDSMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0429726-A1 Process for 2-(aminoalkylthio)carbapenems MERCK & CO. INC. (US) 1991-06-05 EP claimed
US-4894450-A FORMING AN ENOL PHOSPHATE INTERMEDIATE MERCK & CO., INC. (US) 1990-01-16 US claimed
CN-116947924-A Camptothecin biphosphate compound and preparation method thereof 上海应用技术大学 2023-10-27 CN disclosed
US-8883765-B2 Anti-cytomegalovirus activity of artemisinin-derived dimers THE JOHN HOPKINS UNIVERSITY (US) 2014-11-11 US disclosed
US-8883765-B2 Anti-cytomegalovirus activity of artemisinin-derived dimers THE JOHN HOPKINS UNIVERSITY (US) 2014-11-11 US disclosed
US-8883765-B2 Anti-cytomegalovirus activity of artemisinin-derived dimers THE JOHN HOPKINS UNIVERSITY (US) 2014-11-11 US disclosed
US-20130109654-A1 ANTI-CYTOMEGALOVIRUS ACTIVITY OF ARTEMISININ-DERIVED DIMERS THE JOHNS HOPKINS UNIVERSITY (US) 2013-05-02 US disclosed
US-20130109654-A1 ANTI-CYTOMEGALOVIRUS ACTIVITY OF ARTEMISININ-DERIVED DIMERS THE JOHNS HOPKINS UNIVERSITY (US) 2013-05-02 US disclosed
US-20130109654-A1 ANTI-CYTOMEGALOVIRUS ACTIVITY OF ARTEMISININ-DERIVED DIMERS THE JOHNS HOPKINS UNIVERSITY (US) 2013-05-02 US disclosed
WO-2011071981-A2 ANTI-CYTOMEGALOVIRUS ACTIVITY OF ARTEMISININ-DERIVED DIMERS THE JOHNS HOPKINS UNIVERSITY (US) 2011-06-16 WO disclosed
WO-2011071981-A2 ANTI-CYTOMEGALOVIRUS ACTIVITY OF ARTEMISININ-DERIVED DIMERS THE JOHNS HOPKINS UNIVERSITY (US) 2011-06-16 WO disclosed
EP-0679652-A1 Process for preparing carbapenem compounds SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1995-11-02 EP disclosed
EP-0331032-B1 2'-DEOXY-5-FLUOROURIDINE DERIVATIVES TAIHO PHARMACEUTICAL CO., LTD. (JP) 1993-04-28 EP disclosed
US-5032680-A Antitumor KURARAY CO., LTD. (JP) 1991-07-16 US disclosed
EP-0429726-A1 Process for 2-(aminoalkylthio)carbapenems MERCK & CO. INC. (US) 1991-06-05 EP disclosed
US-4992558-A Used for dyeing synthetic materials; polyesters CIBA-GEIGY CORPORATION (US) 1991-02-12 US disclosed
US-4894450-A FORMING AN ENOL PHOSPHATE INTERMEDIATE MERCK & CO., INC. (US) 1990-01-16 US disclosed
EP-0331032-A1 2'-Deoxy-5-fluorouridine derivatives TAIHO PHARMACEUTICAL CO., LTD. (JP) 1989-09-06 EP disclosed
EP-0290583-A1 -g(a) OLIGONUCLEOTIDES. CENTRE NAT RECH SCIENT (FR) 1988-11-17 EP disclosed
WO-1988004301-A1 alpha OLIGONUCLEOTIDES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 1988-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109654-A1 ANTI-CYTOMEGALOVIRUS ACTIVITY OF ARTEMISININ-DERIVED DIMERS EIF2AK2, MAVS, PARP16 MEN1 1379/4885KMT2A 4424/4885HPGD 362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.